The coverage is deep and broad: across the spectrum of development, from basic research through to clinical trials; across a wide range of topics, including data sharing, crucial medicines, psycho-social standards, and survivorship; and across the country and around the world.
Most importantly, that research investment represents a shared aim to find cures for all types of childhood cancer. CAC2 celebrates each and every member’s efforts to help close the large and persistent gap between funding needs to achieve this goal and available resources.
CAC2 doesn’t just applaud our member’s individual efforts but strives to act as a catalyst for research members to work collaboratively to effect positive change in the childhood cancer research community.
Hosting educational conferences and webinars across a multi-disciplinary childhood cancer research audience to encourage exchange of information and build relationships
Providing information to respective members regarding co-funding research projects opportunities typically sourced by a member organization in need of additional funding
Developing online repositories for childhood cancer research progress including:
Establishing the Ethics Think Tank Working Group to help identify best practices and potential ethical issues associated with pediatric cancer charities that fund researchers and the relationships between those organizations and the research recipients.
Assorted News from the Last Week: Accelerated brain aging, atherogenicity, and neurocognition in adult survivors of childhood cancer. The FDA has approved narsoplimab-wuug (Yartemlea) for
Assorted News from the Last Week: Study reveals the profound psychological burden borne not only by childhood cancer survivors but also by their parents, including
Assorted News from the Last Week: CAC2 Board Member Aubrey Reichard-Eline of WITH Grace Initiatives pens powerful Op Ed: “Turning pain into purpose: how service
